

December 24th, 2014
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer

Notice of Revision of the Long Range Plan: FY2014 to FY2016

SymBio today announced a revision of the Long Range Plan, previously disclosed on February 20, 2014, as follows.

(1) Financial Forecast for Fiscal 2014 (January 1, 2014 to December 31, 2014)

	Net Sales	Operating Profit	Ordinary Profit	Net Profit
	In millions of yen	In millions of yen	In millions of yen	In millions of yen
Previous Forecast (A)	1,785	(1,654)	(1,650)	(1,654)
Revised Forecast (B)	1,990	(1,311)	(1,308)	(1,311)
Increase/Decrease (B-A)	205	343	342	343

(2) Rationale for revision

SymBio has revised the Financial Forecast for FY2014 in its Long Range Plan” based on the announcement “Notice of Revision of the Financial Forecast for FY2014” as announced on November 13th, 2014. Also, as for the performance target after FY 2015, it is currently under development, and is scheduled to be promptly disclosed as soon as we have developed.

*Any forward-looking statements in this material, including the forecast of financial results, are estimates based on information available at the time and certain assumptions that SymBio’s management believes to be reasonable. Actual results may differ substantially from such forecasts due to various factors.

[Contact]

Director, Finance & Accounting
 Tetsuya Maruyama
 TEL +81(3)5472-1125